COLTRO, GIACOMO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 2.713
AS - Asia 1.865
EU - Europa 1.804
SA - Sud America 217
Continente sconosciuto - Info sul continente non disponibili 89
AF - Africa 47
OC - Oceania 23
Totale 6.758
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.637
RU - Federazione Russa 743
CN - Cina 600
SG - Singapore 519
IT - Italia 489
HK - Hong Kong 242
KR - Corea 185
BR - Brasile 171
VN - Vietnam 126
IE - Irlanda 124
SE - Svezia 77
FI - Finlandia 76
DE - Germania 65
FR - Francia 63
CH - Svizzera 61
IN - India 59
CA - Canada 43
GB - Regno Unito 33
NL - Olanda 29
BD - Bangladesh 24
AU - Australia 23
ID - Indonesia 23
AR - Argentina 19
JO - Giordania 19
MX - Messico 14
JP - Giappone 11
ES - Italia 8
ZA - Sudafrica 8
CI - Costa d'Avorio 7
IQ - Iraq 7
NG - Nigeria 7
PL - Polonia 7
CO - Colombia 6
MA - Marocco 6
PH - Filippine 6
PK - Pakistan 6
AT - Austria 5
BJ - Benin 5
EC - Ecuador 5
UA - Ucraina 5
UZ - Uzbekistan 5
CR - Costa Rica 4
KE - Kenya 4
MY - Malesia 4
PY - Paraguay 4
TN - Tunisia 4
TR - Turchia 4
AE - Emirati Arabi Uniti 3
BO - Bolivia 3
CL - Cile 3
JM - Giamaica 3
KZ - Kazakistan 3
LB - Libano 3
VE - Venezuela 3
BG - Bulgaria 2
DZ - Algeria 2
IL - Israele 2
KH - Cambogia 2
LI - Liechtenstein 2
LT - Lituania 2
LU - Lussemburgo 2
NP - Nepal 2
OM - Oman 2
RO - Romania 2
SA - Arabia Saudita 2
TT - Trinidad e Tobago 2
UY - Uruguay 2
AL - Albania 1
AW - Aruba 1
AZ - Azerbaigian 1
BB - Barbados 1
BH - Bahrain 1
BT - Bhutan 1
BW - Botswana 1
BZ - Belize 1
CG - Congo 1
CU - Cuba 1
CZ - Repubblica Ceca 1
DO - Repubblica Dominicana 1
GR - Grecia 1
GT - Guatemala 1
HN - Honduras 1
HR - Croazia 1
HU - Ungheria 1
KW - Kuwait 1
LV - Lettonia 1
MN - Mongolia 1
MT - Malta 1
NI - Nicaragua 1
NO - Norvegia 1
PE - Perù 1
PR - Porto Rico 1
SK - Slovacchia (Repubblica Slovacca) 1
SN - Senegal 1
SV - El Salvador 1
TW - Taiwan 1
XK - ???statistics.table.value.countryCode.XK??? 1
YT - Mayotte 1
Totale 6.670
Salva come PNG Salva come JPEG
Città #
Santa Clara 710
Singapore 392
Ashburn 387
San Jose 214
Hefei 213
Hong Kong 209
Seoul 185
Dublin 124
Fairfield 81
Milan 75
Moscow 74
Chandler 68
Beijing 67
Bern 61
Council Bluffs 60
Los Angeles 54
Florence 51
Ho Chi Minh City 48
The Dalles 44
Kent 43
Buffalo 41
Helsinki 38
Woodbridge 38
Cambridge 36
Lauterbourg 36
Seattle 36
Dallas 33
Munich 32
New York 32
Altamura 31
Lawrence 30
Turku 28
Houston 27
Mumbai 27
Hanoi 26
Melbourne 23
Rome 23
Wilmington 23
Phoenix 22
Shanghai 22
Boston 19
Paris 18
Princeton 18
Jakarta 16
London 16
São Paulo 16
Washington 15
Ann Arbor 11
Bengaluru 11
Brooklyn 11
Chicago 11
Bologna 10
Montreal 10
Tianjin 10
Boardman 9
Falkenstein 9
Lappeenranta 9
Tokyo 9
Chennai 8
Naples 8
Sesto Fiorentino 8
Siena 8
Toronto 8
Abidjan 7
Abuja 7
Bremen 7
Modena 7
Orem 7
Rio de Janeiro 7
Amsterdam 6
Atlanta 6
Da Nang 6
Frankfurt am Main 6
Miano 6
Pian di Scò 6
Turin 6
West Jordan 6
Yubileyny 6
Catania 5
Cervia 5
Cotonou 5
Denver 5
Fiesole 5
Johannesburg 5
Medford 5
Miami 5
San Diego 5
Tashkent 5
Warsaw 5
Castel Maggiore 4
Charlotte 4
Clifton 4
Dhaka 4
Haiphong 4
Hillsboro 4
Mexico City 4
Napoli 4
Palermo 4
Pune 4
Redondo Beach 4
Totale 4.227
Salva come PNG Salva come JPEG
Nome #
Compassionate use of JAK1/2 inhibitor ruxolitinib for severe COVID-19: a prospective observational study 280
Involvement of RUNX1 Pathway Is a Common Event in the Leukemic Transformation of Chronic Myeloproliferative Neoplasms (MPNs) 234
A life-threatening ruxolitinib discontinuation syndrome 201
ASXL1 mutations are prognostically significant in PMF, but not MF following essential thrombocythemia or polycythemia vera 200
Phenotypic correlations of CALR mutation variant allele frequency in patients with myelofibrosis 199
JAK2V617F variant allele frequency >50% identifies patients with polycythemia vera at high risk for venous thrombosis 197
The prognostic contribution of CBL, NRAS, KRAS, RUNX1, and TP53 mutations to mutation-enhanced international prognostic score systems (MIPSS70/plus/plus v2.0) for primary myelofibrosis 194
Extramedullary blastic transformation of primary myelofibrosis in the form of disseminated myeloid sarcoma: a case report and review of the literature 193
Italian survey on clinical practice in myeloproliferative neoplasms. A GIMEMA Myeloproliferative Neoplasms Working Party initiative 191
Molecular Characterization of Response/Loss-of-Response to Ruxolitinib in Patients with Myelofibrosis 190
Assessment of the efficacy and tolerability of ruxolitinib for the treatment of myelofibrosis patients in a real-life setting: An Italian MYNERVA Project 182
Integration of multiparameter flow cytometry score improves prognostic stratification provided by standard models in primary myelofibrosis 182
RAS/CBL mutations predict resistance to JAK inhibitors in myelofibrosis and are associated with poor prognostic features 181
Gender and survival in essential thrombocythemia: A two-center study of 1,494 patients 179
Clinical, molecular, and prognostic correlates of number, type, and functional localization of TET2 mutations in chronic myelomonocytic leukemia (CMML)-a study of 1084 patients 178
The Role of Venetoclax in Relapsed/Refractory Acute Myeloid Leukemia: Past, Present, and Future Directions 171
Mutation-enhanced international prognostic systems for essential thrombocythaemia and polycythaemia vera 169
Clinical, Molecular, and Histopathological Correlates in a Series of 24 Consecutive Cases of Suspected Myeloproliferative Neoplasms with a JAK2V617F Variant Allele Frequency≤ 1% 163
Concomitant JAK2 mutated myeloproliferative neoplasms and hereditary hemochromatosis 158
Validation of the IPSET score for thrombosis in patients with prefibrotic myelofibrosis 157
Characteristics and clinical correlates of NFE2 mutations in chronic Myeloproliferative neoplasms 157
Mutations and thrombosis in essential thrombocythemia 151
SF3B1 mutations in primary and secondary myelofibrosis: Clinical, molecular and prognostic correlates 143
Clinicopathologic characteristics, prognostication and treatment outcomes for myelodysplastic/myeloproliferative neoplasm, unclassifiable (MDS/MPN-U): Mayo Clinic-Moffitt Cancer Center study of 135 consecutive patients 142
Classical Philadelphia-negative myeloproliferative neoplasms (MPNs): A continuum of different disease entities 141
Hematologic Neoplasms Associated with Down Syndrome: Cellular and Molecular Heterogeneity of the Diseases 140
RAS mutations drive proliferative chronic myelomonocytic leukemia via a KMT2A-PLK1 axis 140
Chronic Myelomonocytic Leukemia: Insights into Biology, Prognostic Factors, and Treatment 140
Differential prognostic impact of cytopenic phenotype in prefibrotic vs overt primary myelofibrosis 137
Bone marrow dendritic cell aggregates associate with systemic immune dysregulation in chronic myelomonocytic leukemia 135
Validation and molecular integration of the RR6 model to predict survival after 6 months of therapy with ruxolitinib 131
Phenotypic Correlates and Prognostic Outcomes of TET2 Mutations in Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap Syndromes: A Comprehensive Study of 504 Adult Patients 126
The safety of JAK kinase inhibitors for the treatment of myelofibrosis 126
Functional evaluation of isocitrate dehydrogenase 1 and 2 variants of unclear significance in chronic myeloid neoplasms 124
Integration of molecular information in risk assessment of patients with myeloproliferative neoplasms 121
Cutaneous blastic plasmacytoid dendritic cell neoplasm arising in the context of TET2 and ZRSR2 mutated clonal cytopenias of unknown significance, secondary to somatic copy number losses involving CDK2NA/2NB and MTAP 120
Germline SH2B3 pathogenic variant associated with myelodysplastic syndrome/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis 120
Thrombotic risk correlates with mutational status in true essential thrombocythemia 114
Response to erythropoiesis‐stimulating agents in patients with WHO‐defined myelodysplastic syndrome/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis (MDS/MPN‐RS‐T) 111
A challenging diagnosis of myeloid/lymphoid neoplasm with eosinophilia and FIP1L1::PDGFRA rearrangement 109
Clinical and Prognostic Correlates of the Reticulin-Collagen-Osteosclerosis (RCO) Score in Primary Myelofibrosis 106
Spectrum of abnormalities and clonal transformation in germline RUNX1 familial platelet disorder and a genomic comparative analysis with somatic RUNX1 mutations in MDS/MPN overlap neoplasms 104
Landscape of RAS pathway mutations in patients with myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes: a study of 461 molecularly annotated patients 100
Combinatorial BCL2/BCL2L1 expression predicts clinical response to ruxolitinib in myelofibrosis 21
Totale 6.758
Salva come PNG Salva come JPEG
Categoria #
all - tutte 22.346
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 22.346
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022107 0 0 3 1 4 5 0 22 14 1 23 34
2022/2023559 34 87 36 23 56 90 69 21 35 15 16 77
2023/2024445 18 25 56 18 39 75 11 79 12 50 43 19
2024/20252.227 57 206 122 318 562 341 80 107 82 81 129 142
2025/20262.774 304 419 383 263 247 70 300 124 132 196 99 237
2026/2027341 85 63 193 0 0 0 0 0 0 0 0 0
Totale 6.758